Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Double-blind, Randomized, Active-controlled First-in-human Clinical Trial to Evaluate the Safety and Immunogenicity of the Chimeric SpiN-Tec MCTI UFMG Vaccine for Covid19

NCT07134725 is registered in ClinicalTrials.gov with Federal University of Minas Gerais as lead sponsor.

NCT NCT07134725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07134725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Double-blind, Randomized, Active-controlled First-in-human Clinical Trial to Evaluate the Safety and Immunogenicity of the Chimeric SpiN-Tec MCTI UFMG Vaccine for Covid19
Lead sponsor
Federal University of Minas Gerais
Phase
Phase 1/2
Overall status
Completed
Start date
November 23, 2022
Completion date
May 7, 2025
Enrollment
432 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid - 19